Conclusions: The current Italian trial was negative, maybe due to its limitations: lack of power, 1-year follow-up and normal LVMI in some patients at start; however, it was consistent with other published studies. Thus, it is unlikely that targeting hemoglobin in the normal range for CKD patients is of benefit.
PMID: 19034870 [PubMed - as supplied by publisher] (Source: Journal of Nephrology)